ALSF Childhood Cancer Research Grants
With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,500 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
Project Title | Institution / Principal Investigator(s) | Grant Type | Year | State |
---|---|---|---|---|
Targeting Kinase Inhibitor Induced DNA-Damage Response in Ph-Like ALL | Temple University / Christian Hurtz, PhD | 'A' Award Grants | 2022 | Pennsylvania |
Epigenetic therapies to concurrently target DIPG tumor cells and harness the immune system | The Regents of the University of Michigan / Sriram Venneti, MD/PhD | R Accelerated Award Grants | 2022 | Michigan |
Exploiting glypican diversity in neuroblastoma plasticity with bicistronic CAR T cell targeting | Children’s Hospital of Philadelphia / Kristopher Bosse, MD | 'A' Award Grants | 2022 | Pennsylvania |
Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations | The Regents of the University of Michigan / Jolanta Grembecka, PhD | Reach Grants | 2022 | Michigan |
Mechanistic and Therapeutic Development of ATM as a Tumor Cell Selective Target for Radiosensitization in H3K27M DMG | The Regents of the University of Michigan / Meredith Morgan, PhD & Daniel Wahl, MD/PhD | Reach Grants | 2022 | Michigan |
Enhancing TKI Therapy in Ph-Like Leukemia | The Regents of the University of California, Irvine / David Fruman, PhD | Reach Grants | 2022 | California |
Inhibition of translation initiation as a novel therapeutic strategy against MYCN-amplified neuroblastoma | Dana-Farber Cancer Institute / Rani George, MD, PhD | Innovation Grants | 2022 | Massachusetts |
Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia | The Johns Hopkins University School of Medicine / Linda Resar, MD and Jian Jin, PhD | Innovation Grants | 2022 | Maryland |
Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia | Icahn School of Medicine at Mount Sinai / Linda Resar, MD and Jian Jin, PhD | Innovation Grants | 2022 | New York |
Epigenetic Enhancement of MHCI to Augment Neuroblastoma Immunotherapy | University of Wisconsin - Madison / Paul Sondel, MD, PhD and Amy Erbe-Gurel, PhD | Innovation Grants | 2022 | Wisconsin |